Pathologic complete response as a potential surrogate for the clinical outcome in patients with breast cancer after neoadjuvant therapy: A meta-regression of 29 randomized prospective studies

Journal of Clinical Oncology

Volumn 32, Issue 34, 2014, Pages 3883-3891

  Berruti, Alfredo ^a   Amoroso, Vito ^a   Gallo, Fabio ^c   Bertaglia, Valentina ^e   Simoncini, Edda ^b   Pedersini, Rebecca ^b   Ferrari, Laura ^a   Bottini, Alberto ^f   Bruzzi, Paolo ^d   Sormani, Maria Pia ^c  

^a UNIVERSITY OF BRESCIA   (Italy)

^b SPEDALI CIVILI   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

^d UNIVERSITY OF GENOA   (Italy)

^e UNIVERSITY OF TURIN   (Italy)

^f CREMONA HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; METHOTREXATE; TRASTUZUMAB;

BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; DISEASE FREE SURVIVAL; DOSE DENSIFICATION; HUMAN; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE FREE SURVIVAL; REVIEW; SYSTEMATIC REVIEW; TREATMENT RESPONSE; ADJUVANT THERAPY; BIOASSAY; BREAST NEOPLASMS; FEMALE; META ANALYSIS; MORTALITY; PATHOLOGY; RISK; RISK FACTOR; TIME; TREATMENT OUTCOME;

BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; ENDPOINT DETERMINATION; FEMALE; HUMANS; NEOADJUVANT THERAPY; ODDS RATIO; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84912074300     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.55.2836     Document Type: Review

References (56)

1. Chia S, Swain SM, Byrd DR, et al: Locally advanced and inflammatory breast cancer. J Clin Oncol 26:786-790, 2008
2. Berruti A, Brizzi MP, Generali D, et al: Presurgical systemic treatment of nonmetastatic breast cancer: Facts and open questions. Oncologist 13: 1137-1148, 2008
3. Kaufmann M, Hortobagyi GN, Goldhirsch A, et al: Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: An update. J Clin Oncol 24:1940-1949, 2006
4. von Minckwitz G, Untch M, Blohmer JU, et al: Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 30:1796-1804, 2012
5. Chia YH, MJ Ellis MJ, Ma CX: Neoadjuvant endocrine therapy in primary breast cancer: Indications and use as a research tool. Br J Cancer 103:759-764, 2010
6. Burzykowski T, Molenberghs G, Buyse M: The Evaluation of Surrogate Endpoints. New York, NY, Springer, 2005
7. Gail MH, Pfeiffer R, Van Houwelingen HC, et al: On meta-analytic assessment of surrogate outcomes. Biostatistics 1:231-246, 2000
8. Chambers JM: Linear models, in Chambers JM, Hastie TJ (eds): Statistical Models in S. Pacific Grove, CA, Wadsworth & Brooks/Cole, 1992
9. R Core Team: R: A language and environment for statistical computing. Vienna, Austria, R Foundation for Statistical Computing, 2013. http://www.R-project.org/
10. Cocconi G, Di Blasio B, Boni C, et al: Primary chemotherapy in operable breast carcinoma comparing CMF (cyclophosphamide, methotrexate, 5-fluorouracil) with an anthracycline-containing regimen: Short-term responses translated into longterm outcomes. Ann Oncol 16:1469-1476, 2005
11. Buzdar AU, Singletary SE, Theriault RL, et al: Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer. J Clin Oncol 17:3412-3417, 1999
12. Diéras V, Fumoleau P, Romieu G, et al: Randomized parallel study of doxorubicin plus paclitaxel and doxorubicin plus cyclophosphamide as neoadjuvant treatment of patients with breast cancer. J Clin Oncol 22:4958-4965, 2004
13. Smith IC, Heys SD, Hutcheon AW, et al: Neoadjuvant chemotherapy in breast cancer: Significantly enhanced response with docetaxel. J Clin Oncol 20:1456-1466, 2002
14. Heys SD, Sarkar T, Hutcheon AW: Primary docetaxel chemotherapy in patients with breast cancer: Impact on response and survival. Breast Cancer Res Treat 90:169-185, 2005
15. Rastogi P, Anderson SJ, Bear HD, et al: Preoperative chemotherapy: Updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol 26:778-785, 2008
16. Evans TR, Yellowlees A, Foster E, et al: Phase III randomized trial of doxorubicin and docetaxel versus doxorubicin and cyclophosphamide as primary medical therapy in women with breast cancer: An Anglo-Celtic Cooperative Oncology Group study. J Clin Oncol 23:2988-2995, 2005
17. Mansi JL, Yellowlees A, Lipscombe J, et al: Five-year outcome for women randomised in a phase III trial comparing doxorubicin and cyclophosphamide with doxorubicin and docetaxel as primary medical therapy in early breast cancer: An Anglo-Celtic Cooperative Oncology Group study. Breast Cancer Res Treat 122:787-794, 2010
18. Cortés-Flores AO, Morgan-Villela G, Castro-Cervantes JM, et al: Neoadjuvant treatment for locally advanced breast cancer: Comparison of two schemes based on docetaxel-epirubicin vs. 5-fluorouracil-epirubicin-cyclophosphamide. Cir Cir 76:23-28, 2008
19. Bonnefoi H, Piccart M, Bogaerts J, et al: TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): A randomised phase 3 trial. Lancet Oncol 12:527-539, 2011
20. Baldini E, Gardin G, Giannessi PG, et al: Accelerated versus standard cyclophosphamide, epirubicin and 5-fluorouracil or cyclophosphamide, methotrexate and 5-fluorouracil: A randomized phase III trial in locally advanced breast cancer. Ann Oncol 14:227-232, 2003
21. Therasse P, Mauriac L, Welnicka-Jaskiewicz M, et al: Final results of a randomized phase III trial comparing cyclophosphamide, epirubicin, and fluorouracil with a dose-intensified epirubicin and cyclophosphamide + filgrastim as neoadjuvant treatment in locally advanced breast cancer: An EORTC-NCIC-SAKK multicenter study. J Clin Oncol 21:843-850, 2003
22. Frasci G, D'Aiuto G, Comella P, et al: Preoperative weekly cisplatin, epirubicin, and paclitaxel (PET) improves prognosis in locally advanced breast cancer patients: An update of the Southern Italy Cooperative Oncology Group (SICOG) randomised trial 9908. Ann Oncol 21:707-716, 2010
23. Untch M, Möbus V, Kuhn W, et al: Intensive dose-dense compared with conventionally scheduled preoperative chemotherapy for high-risk primary breast cancer. J Clin Oncol 27:2938-2945, 2009
24. Arun BK, Dhinghra K, Valero V, et al: Phase III randomized trial of dose intensive neoadjuvant chemotherapy with or without G-CSF in locally advanced breast cancer: Long-term results. Oncologist 16:1527-1534, 2011
25. Untch M, Fasching PA, Konecny GE, et al: PREPARE trial: A randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel and CMF versus a standard-dosed epirubicin/cyclophosphamide followed by paclitaxel ± darbepoetin alfa in primary breast cancer - Results at the time of surgery. Ann Oncol 22:1988-1998, 2011
26. Untch M, von Minckwitz G, Konecny GE, et al: PREPARE trial: A randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel, and CMF versus a standard-dosed epirubicin-cyclophosphamide followed by paclitaxel with or without darbepoetin alfa in primary breast cancer - Outcome on prognosis. Ann Oncol 22:1999-2006, 2011
27. Ellis GK, Barlow WE, Gralow JR, et al: Phase III comparison of standard doxorubicin and cyclophosphamide versus weekly doxorubicin and daily oral cyclophosphamide plus granulocyte colony-stimulating factor as neoadjuvant therapy for inflammatory and locally advanced breast cancer: SWOG 0012. J Clin Oncol 29:1014-1021, 2011
28. Smith IE, A'Hern RP, Coombes GA, et al: A novel continuous infusional 5-fluorouracil-based chemotherapy regimen compared with conventional chemotherapy in the neo-adjuvant treatment of early breast cancer: 5 year results of the TOPIC trial. Ann Oncol 15:751-758, 2004
29. Chua S, Smith IE, A'Hern RP, et al: Neoadjuvant vinorelbine/epirubicin (VE) versus standard Adriamycin/cyclophosphamide (AC) in operable breast cancer: Analysis of response and tolerability in a randomised phase III trial (TOPIC 2). Ann Oncol 16:1435-1441, 2005
30. Schneeweiss A, Marmé F, Ruiz A, et al: A randomized phase II trial of doxorubicin plus pemetrexed followed by docetaxel versus doxorubicin plus cyclophosphamide followed by docetaxel as neoadjuvant treatment of early breast cancer. Ann Oncol 22:609-617, 2011
31. Schneeweiss A, Ruiz A, Manikhas A, et al: A randomized phase II trial of doxorubicin plus pemetrexed followed by docetaxel versus doxorubicin plus cyclophosphamide followed by docetaxel as neoadjuvant chemotherapy (NACT) for early breast cancer: Three-year follow-up data. J Clin Oncol 30:63s, 2012 (suppl; abstr 1059)
32. Walker LG, Eremin JM, Aloysius MM, et al: Effects on quality of life, anti-cancer responses, breast conserving surgery and survival with neoadjuvant docetaxel: A randomised study of sequential weekly versus three-weekly docetaxel following neoadjuvant doxorubicin and cyclophosphamide in women with primary breast cancer. BMC Cancer 11:179, 2011
33. von Minckwitz G, Rezai M, Loibl S, et al: Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: Phase III GeparQuattro study. J Clin Oncol 28:2015-2023, 2010
34. von Minckwitz G, Rezai M, Fasching PA, et al: Survival after adding capecitabine and trastuzumab to neoadjuvant anthracycline-taxane-based chemotherapy for primary breast cancer (GBG 40-GeparQuattro). Ann Oncol 25:81-89, 2014
35. Kelly CM, Green MC, Broglio K, et al: Phase III trial evaluating weekly paclitaxel versus docetaxel in combination with capecitabine in operable breast cancer. J Clin Oncol 30:930-935, 2012
36. Lee KS, Ro J, Nam BH, et al: A randomized phase-III trial of docetaxel/capecitabine versus doxorubicin/cyclophosphamide as primary chemotherapy for patients with stage II/III breast cancer. Breast Cancer Res Treat 109:481-489, 2008
37. von Minckwitz G, Kümmel S, Vogel P, et al: Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: Phase III randomized GeparTrio trial. J Natl Cancer Inst 100:542-551, 2008
38. von Minckwitz G, Blohmer JU, Costa SD, et al: Response-guided neoadjuvant chemotherapy for breast cancer. J Clin Oncol 31:3623-3630, 2013
39. Buzdar AU, Ibrahim NK, Francis D, et al: Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: Results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 23:3676-3685, 2005
40. Buzdar AU, Valero V, Ibrahim NK, et al: Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: An update of the initial randomized study population and data of additional patients treated with the same regimen. Clin Cancer Res 13:228-233, 2007
41. Gianni L, Eiermann W, Semiglazov V, et al: Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): A randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet 375:377-384, 2010
42. Toi M, Ohno S, Sato N, et al: Preoperative docetaxel (T) with or without capecitabine (X) following epirubicin, 5-fluorouracil and cyclophosphamide (FEC) in patients with operable breast cancer (OOTR N003): Results of comparative study and predictive marker analysis. Cancer Res 72, 2012 (suppl; abstr P1-14-02)
43. Chen X, Ye G, Zhang C, et al: Significantly superior outcome after neoadjuvant chemotherapy with docetaxel, anthracycline and cyclophosphamide versus docetaxel plus cyclophosphamide: Results from the NATT trial in triple negative or HER2 positive breast cancer. Ann Oncol 23, 2012 (suppl; abstr 320PD)
44. Kaufmann M, Eiermann W, Schuette M, et al: Long-term results from the neoadjuvant GeparDuo trial: A randomized, multicenter, open phase III study comparing a dose-intensified 8-week schedule of doxorubicin hydrochloride and docetaxel (ADoc) with a sequential 24-week schedule of doxorubicin hydrochloride/cyclophosphamide followed by docetaxel (AC-Doc) regimen as preoperative therapy (NACT) in patients (pts) with operable breast cancer (BC). J Clin Oncol 28:76s, 2010 (suppl; abstr 537)
45. Mieog JS, van der Hage JA, van de Velde CJ: Preoperative chemotherapy for women with operable breast cancer. Cochrane Database Syst Rev 2:CD005002, 2007
46. Kong X, Moran MS, Zhang N, et al: Metaanalysis confirms achieving pathological complete response after neoadjuvant chemotherapy predicts favourable prognosis for breast cancer patients. Eur J Cancer 47:2084-2090, 2011
47. Prowell TM, Pazdur R: Pathological complete response and accelerated drug approval in early breast cancer. N Engl J Med 366:2438-2441, 2012
48. Gianni L, Pienkowski T, Im YH, et al: Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): A randomised multicentre, open-label, phase 2 trial. Lancet Oncol 13:25-32, 2012
49. European Medicines Agency: EMA/CHMP/151853/2014: Draft guideline on the role of the pathological complete response as an endpoint in neoadjuvant breast cancer studies. http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2014/04/WC500165781.pdf
50. Cortazar P, Zhang L, Untch M, et al: Pathological complete response and long-term clinical benefit in breast cancer: The CTNeoBC pooled analysis. Lancet 384:164-172, 2014
51. Liedtke C, Mazouni C, Hess KR, et al: Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 26:1275-1281, 2008
52. Gianni L, Eiermann W, Semiglazov V, et al: Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): Follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet Oncol 15:640-647, 2014
53. Berruti A, Generali D, Kaufmann M, et al: International expert consensus on primary systemic therapy in the management of early breast cancer: Highlights of the Fourth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2010). J Natl Cancer Inst Monogr 2011:147-151, 2011
54. Buyse M, Sargent DJ, Grothey A, et al: Biomarkers and surrogate end points: The challenge of statistical validation. Nat Rev Clin Oncol 7:309-317, 2010
55. Bonilla L, Ben-Aharon I, Vidal L, et al: Dosedense chemotherapy in nonmetastatic breast cancer: A systematic review and meta-analysis of randomized controlled trials. J Natl Cancer Inst 102:1845-1854, 2010
56. Venturini M, Del Mastro L, Aitini E, et al: Dose-dense adjuvant chemotherapy in early breast cancer patients: Results from a randomized trial. J Natl Cancer Inst 97:1724-1733, 2005